48 results about "CD117" patented technology

The present invention discloses a nucleic acid aptamer binding to CD117 protein and its application, wherein the nucleic acid aptamer has a nucleotide sequence that has at least 60% homology with any one of SEQ ID NO.1 to SEQ ID NO.2 and binds to CD117 protein. The nucleic acid aptamer of the present invention has a small molecular weight, stable structure and chemical properties, is easy to store and label, is easy to modify, and can be artificially synthesized in a short period of time. The nucleic acid aptamer obtained by the present invention can be used for CD117 protein detection, purification or imaging, and can also be used to prepare drugs for diagnosis or treatment of abnormal expression of CD117 protein, such as purification to obtain high-sensitivity and high-specificity detection of CD117 protein, and has broad application prospects.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The present invention relates to a bispecific chimeric antigen receptor targeting CD117 and CD7 and its application, wherein the bispecific chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, wherein the antigen binding domain comprises a CD117 binding domain and a CD7 binding domain. The bispecific chimeric antigen receptor provided by the present invention combines targeted antibodies for CD117 and CD7 together, recognizes and binds to two different antigens at the same time, enhances the targeted elimination ability of malignant cells, and by acting on hematopoietic stem cells and immune cells at the same time, can more effectively eliminate tumor cells in the receptor, while retaining or reconstructing normal hematopoietic and immune functions.

The present invention provides an antibody composition for detecting multiple myeloma based on full-spectrum flow cytometry and its application, belonging to the technical field of multiple myeloma detection. The antibody composition includes CD3 antibody, CD20 antibody, HLA-DR antibody, CD8 antibody, CD11b antibody, CD10 antibody, CD71 antibody, CD28 antibody, CD14 antibody, CD13 antibody, Igκ antibody, CD15 antibody, Igλ antibody, CD117 antibody, CD56 antibody, CD45 antibody, CD19 antibody, CD34 antibody, CD138 antibody, CD4 antibody, CD38 antibody, CD22 antibody and CD27 antibody. The kit containing the antibody composition can be applied to a full-spectrum flow cytometer to accurately perform preliminary screening on patients with multiple myeloma.

The invention relates to an antibody composition, a kit and a system for rapidly screening acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD71 antibody, a CD33 antibody, a CD117 antibody, a CD34 antibody, an HLA-DR antibody, a CD19 antibody, a CD10 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises a CD38 antibody, a CD56 antibody, a CD16 antibody, a CD34 antibody, a CD13 antibody, a CD11b antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; the third group of antibodies comprises a CD9 antibody, an MPO antibody, a CD117 antibody and a CD45 antibody; and each antibody is a monoclonal antibody marked with a detection marker. The antibody composition comprises a CD117 + CD33 + region as a main target cell population, and covers three groups of antibodies for identifying acute promyelocytic leukemia, such as CD33, CD34, CD64, CD13, CD9 and MPO, the acute promyelocytic leukemia can be rapidly, simply and conveniently detected by adopting the antibody composition, the detection sensitivity is high, the specificity is high, the accuracy rate is high, and the antibody composition can be widely applied to detection of acute promyelocytic leukemia. The acute promyelocytic leukemia patient can be accurately and quickly identified, and early diagnosis and early treatment are realized.

The invention relates to a nano antibody targeting CD117 and application of the nano antibody. The invention also relates to a CD117-targeting antibody or an antigen binding fragment thereof and an application of the CD117-targeting antibody or the antigen binding fragment thereof.

The present invention relates to a CD117 antibody and a delivery vector using same, such as lipid nanoparticles (LNPs). Further provided in the present invention are a method for delivering a bioactive substance to CD117+ cells by using the delivery vector and a method for preparing such a lipid nanoparticle conjugate.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

The invention relates to the technical field of biological medicine, in particular to application of S100A9 protein to preparation of a product for predicting the recurrence risk of AML. The product is used for detecting a marker CD15, a marker CD33, a marker CD14, a marker CD15, a marker CD33, a marker CD64, a marker CD5, a marker CD14, a marker CD10, a marker CD19, a marker CD33, a marker CD34, a marker CD64, a marker CD117, a marker CD13 or a marker CD45. Therefore, the accuracy of predicting the AML recurrence risk is improved.

Provided herein are bispecific antibodies comprising a first antigen-binding region and a second antigen-binding region wherein the first antigen-binding region binds CD117 and comprises a first heavy chain variable region and a first light chain variable region and the second antigen-binding region binds CD3 and comprises a second heavy chain variable region and a second light chain variable region. Also provided herein are compositions comprising the bispecific antibodies and uses of the bispecific antibodies and compositions.

The present disclosure relates to antibodies and antibody fragments specific to CD117. The antibody is an improved version of state-of-the-art antibodies. In addition to the strategy of sophisticated humanization, the antibody was also modified to remove some deleterious motifs within the CDR regions without losing beneficial properties. The antibody is useful for the treatment of diseases associated with CD117.

The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.

This application relates to a nanobody targeting CD117 and its application. This application also relates to an antibody targeting CD117 or its antigen-binding fragment and its application.

The present invention relates to CD117 targeted LNP molecules for delivery of pro-apoptotic mRNA to hematopoietic stem cells (HSCs) and methods of use thereof for preconditioning a subject for hematopoietic stem cell therapy or to deplete the subject's HSC population for the treatment of a disease or disorder.

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

The present invention provides an anti-human CD117 monoclonal antibody and a use thereof. The anti-human CD117 monoclonal antibody of the present invention comprises three heavy chain complementarity-determining regions CDR-H1, CDR-H2 and CDR-H3 having amino acid sequences as shown in SEQ ID NOs. 1-3, respectively, and three light chain complementarity-determining regions CDR-L1, CDR-L2 and CDR-L3 having amino acid sequences as shown in SEQ ID NOs. 4-6, respectively. The antibody shows good activity at cytology level.

The present invention relates to recombinant binding proteins comprising a first designed ankyrin repeat domain which has a first binding specificity for a first target and a second binding specificity for a second target, wherein the binding of said first domain to said first and second targets is mutually exclusive, and wherein the first target is CD117 and the second target is a CD47-specific binding agent. The invention also provides further recombinant proteins comprising said first dual-specific repeat domain and additional therapeutic agents such as binding agents. Further disclosed are nucleic acids encoding such recombinant proteins, pharmaceutical compositions comprising such recombinant proteins or nucleic acids and the use of such recombinant proteins, nucleic acids or pharmaceutical compositions in methods for treating diseases, such as cancer in a mammal, including a human. Designed ankyrin repeat domains with binding specificity for a CD47-specific ankyrin repeat domain are also disclosed.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Compositions and methods for non-genotoxic monoclonal antibody (mAb) conditioning, wherein the methods involve altering differentiation cluster 117 (CD117; 117 ') in hematopoietic stem cells (HSCs) or progenitor cells thereof. C-KIT) polynucleotide sequences to encode a CD117 polypeptide with reduced binding to the antibody. In various embodiments, the method further comprises introducing a therapeutic alteration into the gene of the HSC or progenitor cell thereof for the treatment of hemoglobinopathy.

The invention belongs to the technical field of immunological detection, and discloses an antibody composition for detecting early precursor acute T-cell lymphocytes, which comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD99 antibody, a CD4 antibody, a CD34 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD117 antibody, a CD13 antibody, a CD11b antibody, a CD7 antibody, a CD64 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a TdT antibody, an MPO antibody, a CD10 antibody, a CD1a antibody, a cCD3 antibody, a CD7 antibody, a CD19 antibody, a cCD22 antibody and a CD45 antibody; each antibody is a monoclonal antibody marked with a detection marker. The antibody composition can be used for rapidly, accurately and comprehensively detecting early-stage precursor T cell acute lymphocytes at one time.

To provide acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.SOLUTION: There is provided an isolated immunoresponsive cell comprising (a) a first chimeric receptor comprising an extracellular antigen-binding domain that binds to a first antigen, and (b) a second chimeric receptor comprising an extracellular antigen-binding domain that binds to a second antigen, wherein each antigen is selected from a group consisting of FLT3, CD33, CLEC12A, MS4A3, VSTM1, LAT2, MLC1, CD131, GAPT, PRAM1, SLC22A16, SLC17A9, SPNS3, ADGRE2, IL3RA, CD117, CD93, IL1RAP, CD244, CCR1, LILRB2, PIEZO1, CD38, EMB, MYADM, LILRA2, CD300LF, and CD70, and wherein the first antigen is different from the second antigen.SELECTED DRAWING: Figure 1

The invention provides an antibody composition for detecting AML (acute myeloid leukemia) accompanied with CBF beta MYH11. The antibody composition comprises CD2, CD34, CD117, CD64, CD14, CD33, HLA-DR (human leukocyte antigen-DR), CD15, CD11b, CD13, CD38 and CD45 antibodies. During detection, the antibody composition is divided into two types of antibody combinations according to detection targets, and then samples are respectively added for flow cytometry detection; when the proportion of original myeloid cells / nucleated cells is between 6% and 78%, the proportion of mononuclear cells / nucleated cells is greater than 22%, and the proportion of CD2 / mononuclear cells is greater than 20%, determining that the sample is AML with CBF beta MYH11. The method provided by the invention is simple and low in cost, can be used for judging whether the AML patient has CBF beta MYH11 positive or not without further molecular biological PCR (Polymerase Chain Reaction) screening, and has a great practical value.

Among the various aspects of the present disclosure is the provision of conditioning agents for use in allogeneic hematopoietic stem cell transplantation. An aspect of the present disclosure provides for a method of treating a subject or inhibiting alloreactivity in the host-versus-graft direction comprising administering a combination of conditioning agents comprising an anti-body-drug conjugate (ADC) and a JAK1 / JAK2 inhibitor for use in allogeneic hematopoietic stem cell transplantation in an amount sufficient to permit engraftment of allogeneic bone marrow. In some embodiments, the ADC is selected from CD45-SAP, cKit-SAP, CD117-Amanitin, and CD45-PBD. In some embodiments, the JAK1 / JAK2 inhibitor is selected from baricitinib and ruxolitinib. In some embodiments, the method further comprises administering a cancer therapeutic.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Provided are an anti-human CD117 nanobody and use thereof. The nanobody comprises at least one VHH chain. The VHH chain comprises a CDR1, a CDR2, and a CDR3. The amino acid sequence of the CDR1 is set forth in SEQ ID NO: 4, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 5, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 6; or the amino acid sequence of the CDR1 is set forth in SEQ ID NO: 7, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 8, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 9; or the amino acid sequence of the CDR1 is set forth in SEQ ID NO: 10, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 11, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 12. The use is use of the nanobody and a formulation thereof in the preparation of a drug for treating thalassemia. The nanobody has a good binding ability to CD117, and has the advantages of small molecular weight, high binding activity, low immunogenicity, easy modification, etc.

This invention relates to an antibody composition, kit, and system for rapid screening of acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies, and a third group of antibodies. The first group of antibodies comprises antibodies against CD71, CD33, CD117, CD34, HLA-DR, CD19, CD10, CD7, and CD45. The second group of antibodies comprises antibodies against CD38, CD56, CD16, CD34, CD13, CD11b, CD64, CD15, and CD45. The third group of antibodies comprises antibodies against CD9, MPO, CD117, and CD45. Each of the antibodies is a monoclonal antibody labeled with a detection marker. The antibody composition contains a cell population targeting the CD117+CD33+ region, and includes three groups of antibodies that recognize acute promyelocytic leukemia, including CD33, CD34, CD64, CD13, CD9, and MPO. Using this antibody composition, acute promyelocytic leukemia can be detected quickly and easily with high sensitivity, specificity, and accuracy. It can accurately and rapidly identify patients with acute promyelocytic leukemia, enabling early diagnosis and treatment.

The application provides a cell identification kit and a use method and application thereof in identifying mast cells, and relates to the technical field of cell identification. The cell identification kit comprises CD117 antibody conjugated magnetic microparticles, CD16 antibody conjugated magnetic microparticles and Fc epsilon R1 alpha antibody conjugated magnetic microparticles, and FcR blocking agent and eluent. The cell identification kit can be used to identify one or more of CD117, Fc epsilon R1 alpha and CD16 on the surface of cells, and target cells with a purity of at least 90% can be obtained. The application is applied to identifying whether a cell is CD117 + Fc epsilon R1 alpha + CD16 ‑ mast cells, target cells with a purity higher than 95% can be obtained, the degranulation rate of mast cells is improved, and the technical problem of a low degranulation rate of mast cells obtained by a mast cell identification method in the prior art is solved.

Compositions and methods for non-genotoxic monoclonal antibody (mAb) conditioning, where the methods involve altering a cluster of differentiation 117 (CD117; c-KIT) polynucleotide sequence in a hematopoietic stem cell (HSC) or progenitor thereof to encode a CD117 polypeptide with reduced binding to the antibody. In various embodiments, the methods further include introducing a therapeutic alteration to a gene of the HSC or progenitor thereof for treatment of a hemoglobinopathy.